Body Mass Index, IL-6 Signaling, and Multiple Sclerosis: Uncovering a Causal Inflammatory Pathway
Multiple sclerosis (MS) is a complex immune-mediated disease of the central nervous system in which both genetic susceptibility and environmental exposures contribute to disease onset. Among modifiable risk factors, elevated body mass index (BMI) has repeatedly emerged as an important determinant of MS susceptibility. The article by Vandebergh and colleagues addresses a key mechanistic question within this association: does obesity increase MS risk partly through interleukin-6 (IL-6) signaling, a major inflammatory pathway linked to adipose tissue biology? By focusing on this question, the study moves beyond simple epidemiologic association and attempts to identify a biologically plausible mediator between excess adiposity and autoimmune neuroinflammation.
Study Rationale: Why IL-6 Signaling Matters
The scientific premise of the study is compelling. Obesity is characterized by a chronic low-grade inflammatory state, and IL-6 is one of the cytokines most consistently elevated in this context. Prior Mendelian randomization studies had already shown that higher BMI is likely to increase the risk of MS, but much of that effect remained unexplained. Earlier work suggested that vitamin D accounts for only a small fraction of the BMI–MS relationship, and other candidate mediators such as leptin and adiponectin had not provided convincing evidence. The authors therefore proposed that IL-6 signaling might represent a major inflammatory bridge between obesity and MS susceptibility, making it a strong candidate for causal mediation analysis.
Methodological Framework: Mendelian Randomization as a Causal Tool
To investigate this hypothesis, the authors used a two-sample Mendelian randomization design, an approach that leverages genetic variants as proxies for exposures in order to strengthen causal inference. They assembled genome-wide association study data for BMI, IL-6 signaling, circulating IL-6 levels, C-reactive protein (CRP), and MS susceptibility. Their MS dataset included 14,802 cases and 26,703 controls from the International Multiple Sclerosis Genetics Consortium. The analytical strategy included both univariable Mendelian randomization, to test pairwise causal effects, and multivariable Mendelian randomization, to determine whether IL-6 signaling mediates the effect of BMI on MS risk. This design is especially valuable because it reduces confounding and reverse causation, two persistent problems in conventional observational epidemiology.
Principal Findings: BMI and IL-6 Signaling Both Increase MS Risk
The results were notable. Genetically predicted higher BMI was associated with a significantly increased risk of MS, with an odds ratio of 1.30. Genetically predicted increased IL-6 signaling was also associated with higher MS risk, with effect estimates that were statistically significant across the main analyses. By contrast, genetically predicted circulating IL-6 levels alone did not show convincing evidence of an effect on MS, and neither did CRP itself when analyzed independently. This distinction is important: the study suggests that the pathogenic relevance lies not simply in the quantity of circulating IL-6 or CRP, but in the biology of IL-6 receptor-mediated signaling. The forest plots on pages 5 and 6 reinforce this interpretation by showing stronger and more consistent effects for IL-6 signaling proxies than for serum IL-6 or CRP alone.
Mediation Analysis: Quantifying the Inflammatory Pathway
One of the most important contributions of the paper is its mediation analysis. The authors found that higher genetically predicted BMI strongly increased IL-6 signaling, while IL-6 signaling did not appear to increase BMI in the reverse direction. In multivariable Mendelian randomization models, both BMI and IL-6 signaling retained associations with MS risk, but the effect of BMI was attenuated after adjustment for IL-6 signaling. From these estimates, the authors calculated that approximately 43% of the effect of BMI on MS risk is mediated through IL-6 signaling, with a confidence interval of 25% to 54%. The directed acyclic graph on page 3 clarifies this conceptual model by showing BMI as the exposure, IL-6 signaling as the mediator, and MS susceptibility as the outcome.
Biological Interpretation: From Adipose Inflammation to Autoimmunity
These findings have important biological implications. They support a model in which excess adiposity promotes a pro-inflammatory milieu that enhances IL-6 signaling and thereby contributes to autoimmune processes relevant to MS. The discussion in the article also situates these results within a broader immunological framework. The authors note that IL-6 signaling is complex, involving classical, trans, and cluster signaling modes, and that its effects may differ across cell types. They further connect their genetic findings with experimental evidence showing that blockade of IL-6 receptor signaling can reduce pathogenic T-cell responses and suppress experimental autoimmune encephalomyelitis, an animal model of MS. Together, these converging lines of evidence strengthen the idea that IL-6 signaling is not merely correlated with MS risk, but mechanistically relevant to disease development.
Strengths, Limitations, and Broader Significance
The study is methodologically rigorous, with multiple sensitivity analyses addressing pleiotropy, heterogeneity, and potential bias from major histocompatibility complex variants. At the same time, the authors appropriately acknowledge limitations, including restriction to individuals of European ancestry, the lifelong nature of genetic proxies compared with short-term therapeutic intervention, and the possibility of residual pleiotropy that cannot be entirely excluded. Even so, the study substantially advances understanding of the obesity–MS connection by identifying IL-6 signaling as a major mediator. It also leaves open an important question: if IL-6 explains about 40% of the BMI effect, what explains the remainder? The authors suggest that additional inflammatory mediators, metabolites, and gut microbiota pathways deserve further study. As a result, this paper is significant not only for MS biology, but also for preventive medicine, because it frames obesity-related inflammation as a potentially actionable pathway in autoimmune disease risk.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Chen, M., Zhao, D., Fan, H. et al. Integrated multi-omics and machine learning prioritize key immune genes for multiple sclerosis risk prediction. Mamm Genome 37, 38 (2026). https://doi.org/10.1007/s00335-026-10207-6
